Da de aktive stoffer i Trizivir eventuelt kan hæmme DNA - replikation, udgør enhver anvendelse, specielt i første trimester, en potentiel risiko for fosteret.
As the active substances of Trizivir may inhibit DNA replication any use, especially during the first trimester, presents a potential risk to the foetus.